Search
Vabametkib
go.drugbank.com/drugs/DB21629InvestigationalVabametkib is under investigation in clinical trial NCT05541822 (To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET
Ularitide
go.drugbank.com/drugs/DB05034InvestigationalWhen injected into the blood, ularitide appears to cause diuresis (urine output) and natriuresis (sodium excretion), as well as vasodilation.
Mizoribine
go.drugbank.com/drugs/DB12617InvestigationalMizoribine has been investigated for the treatment of Rheumatoid Arthritis.
Categories: Analgesics, Non-NarcoticPyridoxal phosphate
go.drugbank.com/drugs/DB00114ApprovedInvestigationalNutraceuticalThis is the active form of vitamin B6 serving as a coenzyme for synthesis of amino acids, neurotransmitters (serotonin, norepinephrine), sphingolipids, aminolevulinic acid. During transamination of amino acids, pyridoxal phosphate is tra...
St. John's Wort
go.drugbank.com/drugs/DB01323ApprovedInvestigationalNutraceuticalCategories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeLomerizine
go.drugbank.com/drugs/DB14065Experimental[A245383] This drug is used to prophylactically treat migraines[A245368, A245373] and is also being investigated against eye-related diseases that are associated with local circulatory disturbances, an
Tesaglitazar
go.drugbank.com/drugs/DB06536InvestigationalTesaglitazar is a dual peroxisome proliferator-activated receptor alpha/gamma agonist which improves apolipoprotein levels in non-diabetic subjects with insulin resistance.
Bimoclomol
go.drugbank.com/drugs/DB06258ExperimentalBimoclomol is an investigational drug that induces stress proteins and has cytoprotective effects.
Sacrosidase
go.drugbank.com/drugs/DB06760ApprovedSacrosidase is a liquid enzyme preparation from S.cerevisiae used for the treatment of congenital sucrose-isomaltase deficiency (CSID). People with CSID have variable amounts of sucrose-isomaltase enzyme activity and therefore have issue...
QazCovid-in
go.drugbank.com/drugs/DB16441InvestigationalIt demonstrated high efficacy, safety, and immunogenicity at 96% in initial Phase I and II trials (NCT04530357), and will now be undergoing upcoming Phase III trials[L30633, L30638].